Galantamine in the Treatment of Post-Traumatic Headache

Unknown statusPhase 4NCT00219869

View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

Most patients with CPTH present with additional major cognitive, behavioral and somatic problems. Most drugs used currently have a negative influence on cognition. Therefore, treatment strategies addressing both the headache and cognitive disturbances in patients with CPTH are necessary. (CPTH; Chronic Post Traumatic Headache).

Study details

Official title: Galantamine in the Preventive Treatment of Chronic Post-Traumatic Headache
Conditions: Post-Traumatic Headache
Head Trauma,Closed
Retention Disorders,Cognitive
Interventions: Drug: Galantamine
Sponsor: Rapoport, Alan, M.D.
Collaborators: Ortho-McNeil Neurologics, Inc.
Start date: 2005-07
Sex: All
Age range: from 18 Years to 75 Years
Healthy volunteers: true
Results posted: No results posted in this snapshot
Countries: United States
Total sites listed: 1

Eligibility criteria

Show eligibility criteria (verbatim from the registry)

Inclusion Criteria: Age range 18-75 CPTH according to ICHD-2 Fertile woman using adequate birth control Willing and able to give informed consent Willing and able to complete the entire course of the study to comply with study instructions Stable does of preventive medication \- Exclusion Criteria: Subject is pregnant or lactating Significant medical or psychiatric disease Previous failure to 4 or more adequate trials of preventive medication Patient on non-stable dose of medication used to prevent CPTH \-

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00219869